

Approving children's cancer drugs takes 6.5 years longer

June 12 2019



(HealthDay)—For cancer drugs ultimately approved by the U.S. Food

and Drug Administration, the median lag time from first-in-human to first-in-child trials is 6.5 years, according to a study published in the May issue of the *European Journal of Cancer*.

Dylan V. Neel, from Harvard University in Boston, and colleagues conducted a systematic analysis of time from first-in-[human trials](#) to first-in-child trials (age of eligibility

Citation: Approving children's cancer drugs takes 6.5 years longer (2019, June 12) retrieved 7 July 2024 from <https://medicalxpress.com/news/2019-06-children-cancer-drugs-years-longer.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.